An apolar extract of Critonia morifolia inhibits c-Myc, cyclin D1, Cdc25A, Cdc25B, Cdc25C and Akt and induces apoptosis

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 2131-2139

  Unger, Christine ^a   Popescu, Ruxandra ^b   Giessrigl, Benedikt ^a   Rarova, Lucie ^c   Herbacek, Irene ^a   Seelinger, Mareike ^a   Diaz, Rene ^d   Wallnöfer, Bruno ^e   Fritzer Szekeres, Monika ^a   Szekeres, Thomas ^a   Frisch, Richard ^d   Doležal, Karel ^c   Strnad, Miroslav ^c   De Martin, Rainer ^a   Grusch, Michael ^a   Kopp, Brigitte ^b   Krupitza, Georg ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d Institute for Ethnobiology   (Guatemala)

^e NATURHISTORISCHES MUSEUM WIEN   (Austria)

Author keywords

Akt; Anti neoplastic; Cdc25; Critonia morifolia; Cyclin d1; Healing plant

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CHECKPOINT KINASE 2; CRITONIA MORIFOLIA EXTRACT; CYCLIN D1; HISTONE H2AX; MYC PROTEIN; PETROLEUM; PLANT EXTRACT; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASTERACEAE; ATTENUATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRITONIA MORIFOLIA; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MEDICINAL PLANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAIN FOREST; S PHASE CELL CYCLE CHECKPOINT;

ALKANES; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTERACEAE; CDC25 PHOSPHATASES; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; SOLVENTS;

EID: 84861767292     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1412     Document Type: Article

References (40)

1. Cragg GM and Newman DJ: Natural Product Sources of Drugs: Plants, Microbes, Marine Organisms, and Animals. Comprehensive Medicinal Chemistry II, Chapter 1.08: 355-403, 2007.
2. Koehn FE and Carter GT: The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206-220, 2005. (Pubitemid 40372555)
3. Newman DJ and Cragg GM: Anticancer Agents from Natural Sources. Cragg GM, Kingston DGI and Newman DJ (eds). CRC Press/Taylor & Francis, Boca Raton, FL, pp553-571, 2005.
4. Kinghorn P and Fletcher C: The relevance of higher plants in lead discovery programs. J Nat Prod 74: 1539-1555, 2011.
5. Li JW and Vederas JC: Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161-165, 2009.
6. Herz W: Chemistry of the Critoniinae. Biochem Syst Ecol 32: 1159-1185, 2004.
7. Arvigo R and Balick M: Rainforest Remedies. 2nd edition. Lotus Press, Twin Lakes, WI, 1998.
8. Zhang JS, Nelson M, Wang L, Liu W, Qian CP, Shridhar V, Urrutia R and Smith DI: Identification and chromosomal localization of CTNNAL1, a novel protein homologous to alpha-catenin. Genomics 54: 149-154, 1998. (Pubitemid 28536205)
9. Strasser S, Maier S, Leisser C, Saiko P, Madlener S, Bader Y, Bernhaus A, Gueorguieva M, Richter S, Mader RM, Wesierska-Gadek J, Schott H, Szekeres T, Fritzer-Szekeres M and Krupitza G: 5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2. Differentiation 74: 488-498, 2006. (Pubitemid 44922494)
10. Maier S, Strasser S, Saiko P, Leisser C, Sasgary S, Grusch M, Madlener S, Bader Y, Hartmann J, Schott H, Mader RM, Szekeres T, Fritzer-Szekeres M and Krupitza G: Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC. Apoptosis 11: 427-440, 2006.
11. Hüttenbrenner S, Maier S, Leisser C, Polgar D, Strasser S, Grusch M and Krupitza G: The evolution of cell death programs as prerequisites of multicellularity. Rev Mutat Res 543: 235-249, 2003. (Pubitemid 36645082)
12. Grusch M, Fritzer-Szekeres M, FuhrmannG, Rosenberger G, Luxbacher C, Elford HL, Smid K, Peters GJ, Szekeres T and Krupitza G: Activation of caspases and induction of apoptosis by amidox and didox. Exp Haematol 29: 623-632, 2001.
13. Gridling M, Stark N, Madlener S, Lackner A, Popescu R, Benedek B, Diaz R, Tut FM, Vo NTP, Huber D, Gollinger M, Saiko P, Özmen A, Mosgoeller W, De Martin R, Eytner R, Wagner KH, Grusch M, Fritzer-Szekeres M, Szekeres T, Kopp B, Frisch R and Krupitza G: In vitro anti-cancer activity of two ethno-pharmacological healing plants from Guatemala Pluchea odorata and Phlebodium decumanum. Int J Oncol 34: 1117-1128, 2009.
14. Madlener S, Svacinová J, Kitner M, Kopecky J, Eytner R, Lackner A, Vo NTP, Frisch R, Grusch M, De Martin R, Dolezal K, Strnad M and Krupitza G: In vitro anti-inflammatory and anticancer activities of extracts of Acalypha alopecuroidea (Euphorbiaceae). Int J Oncol 35: 881-891, 2009.
15. Hunter T: Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80: 225-236, 1995.
16. Norbury C, Blow J and Nurse P: Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J 10: 3321-3329, 1991. (Pubitemid 21905357)
17. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J and Dalla-Favera R: Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451, 2007. (Pubitemid 47123512)
18. Fu M, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447, 2004. (Pubitemid 39564581)
19. Abukhdeir AM and Park BH: P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 10: e19, 2008.
20. Zhou BB and Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 408: 433-439, 2000.
21. Koczor CA, Shokolenko IN, Boyd AK, Balk SP, Wilson GL and Ledoux SP: Mitochondrial DNA damage initiates a cell cycle arrest by a Chk2-associated mechanism in mammalian cells. J Biol Chem 284: 36191-36201, 2009.
22. Mazzacurati L, Pattacini L, Brusa G, Mancini M, Benvenuti M, Barbieri E, Martinelli G, Baccarani M, Greenberger JS and Santucci MA: Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571. Hematol J 5: 168-177, 2004. (Pubitemid 38519267)
23. MAPK, Chk2 and 14.3.3. Hum Mol Genet 18: 1990-2000, 2009.
24. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, De Mayo F, Bradley A, Donehower LA and Elledge SJ: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14: 1448-1459, 2000. (Pubitemid 30421838)
25. Fernandes-Alnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269: 30761-30764, 1994. (Pubitemid 24377553)
26. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM: DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868, 1998. (Pubitemid 28124064)
27. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS and Tolcher AW: First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29: 4688-4695, 2011.
28. Franke TF, Kaplan DR and Cantley LC: PI3K: downstream AKTion blocks apoptosis. Cell 88: 435-437, 1997. (Pubitemid 27154408)
29. Hers I, Vincent EE and Tavaré JM: Akt signalling in health and disease. Cell Signal 23: 1515-1527, 2011.
30. Wiedenfeld H and Cetto A: Pyrrolizidine alkaloids from Critonia morifolia. Phytochemistry 49: 1463-1465, 1998. (Pubitemid 28524974)
31. Pines J: Cyclins: wheels within wheels. Cell Growth Differ 2: 305-310, 1991.
32. Lingfei K, Pingzhang Y, Zhengguo L, Jianhua G and Yaowu Z: A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. Cancer Lett 130: 93-101, 1998. (Pubitemid 28425342)
33. Hoffmann I, Draetta G and Karsenti E: Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J 13: 4302-4310, 1994. (Pubitemid 24295202)
34. Kiyokawa H and Ray D: In vivo roles of CDC25 phosphatases: biological insight into the anti-cancer therapeutic targets. Anticancer Agents Med Chem 8: 832-836, 2008.
35. Nilsson I and Hoffmann I: Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 4: 107-114, 2000.
36. Lammer C, Wagerer S, Saffrich R, Mertens D, Ansorge W and Hoffmann I: The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J Cell Sci 111: 2445-2453, 1998. (Pubitemid 28434930)
37. Ferguson AM, White LS, Donovan PJ and Piwnica-Worms H: Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol Cell Biol 25: 2853-2860, 2005. (Pubitemid 40381646)
38. McGowan CH and Russell P: Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 12: 75-85, 1993. (Pubitemid 23042384)
39. Ahn JY, Schwarz JK, Piwnica-Worms H and Canman CE: Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 60: 5934-5936, 2000.
40. Mailand N, Falck J, Lukas C, Syljuâsen RG, Welcker M, Bartek J and Lukas J: Rapid destruction of human Cdc25A in response to DNA damage. Science 288: 1425-1429, 2000. (Pubitemid 30366329)